title: Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction.
abstract: In a previous study on the diagnostic efficiency of troponin T measurements in patients with suspected acute myocardial infarction (AMI), the authors found a high variability of troponin T serum concentration changes on day 1 in patients with AMI who underwent thrombolytic treatment. Therefore, the aims of the present study were to investigate the intracellular compartmentation of troponin T and to analyze the effects of AMI reperfusion on the appearance kinetics of cardiac troponin T in serum. Cardiac troponin T was measured with a newly developed bideterminant sandwich assay using cardiospecific, affinity-purified polyclonal antibodies and peroxidase-labeled monoclonal antibody. An unbound cytosolic troponin T pool was found in ultracentrifuged homogenates of myocardial tissue of different species ranging from 0.013 to 0.036 mg/g wet weight. The soluble troponin T molecule had electrophoretic properties identical to troponin T compartmented in the myofibrils. The clinical study group comprised 57 patients with AMI undergoing thrombolytic treatment. Blood flow to the infarct zone and point of time of reperfusion were tested by immediate and late angiography. The appearance of troponin T in serum on day 1 after the onset of AMI depended strongly on reperfusion and on duration of ischemia before reperfusion. Thus, in patients with early reperfused AMI, a marked peak in troponin T serum concentrations was found at 14 hours after the onset of pain. This early troponin T peak was absent in patients with AMI reperfusion occurring greater than 5.5 hours after the onset of pain and in patients with nonreperfused AMI. By contrast, the kinetics of troponin T release after the first day after AMI were unaffected by reperfusion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Innere Medizin III, University of Heidelberg, Federal Republic of Germany.
authors.forename: H A
authors.initials: HA
authors.lastname: Katus
authors.forename: A
authors.initials: A
authors.lastname: Remppis
authors.forename: T
authors.initials: T
authors.lastname: Scheffold
authors.forename: K W
authors.initials: KW
authors.lastname: Diederich
authors.forename: W
authors.initials: W
authors.lastname: Kuebler
mesh_terms: D000818:Animals; D002417:Cattle; D017023:Coronary Angiography; D003402:Creatine Kinase / Q000378:metabolism; D004285:Dogs; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000628:therapy; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000378:metabolism; D010960:Plasminogen Activators / Q000627:therapeutic use; D051381:Rats; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014336:Troponin / Q000097:blood*; D020107:Troponin T; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014336:Troponin; D020107:Troponin T; D003402:Creatine Kinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator